Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

VolitionRx (VNRX) is targeting a ~$36B TAM in early cancer detection and MRD, signaling an expansion of its commercial opportunity. The company says it is in active discussions with global diagnostic leaders to accelerate commercialization. The update appears promotional and strategy-focused, with limited immediate read-through to near-term financials.

Analysis

VolitionRx (VNRX) is targeting a ~$36B TAM in early cancer detection and MRD, signaling an expansion of its commercial opportunity. The company says it is in active discussions with global diagnostic leaders to accelerate commercialization. The update appears promotional and strategy-focused, with limited immediate read-through to near-term financials.